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ABSTRACT
Objectives: To evaluate risk factors associated with
exacerbation frequency in primary care. Information on
exacerbations of chronic obstructive pulmonary disease
(COPD) has mainly been generated by secondary care-
based clinical cohorts.
Design: Retrospective observational cohort study.
Setting: Electronic medical records database (England
and Wales).
Participants: 58 589 patients with COPD aged
≥40 years with COPD diagnosis recorded between
1 April 2009 and 30 September 2012, and with at least
365 days of follow-up before and after the COPD
diagnosis, were identified in the Clinical Practice
Research Datalink. Mean age: 69 years; 47% female;
mean forced expiratory volume in 1s 60% predicted.
Outcome measures: Data on moderate or severe
exacerbation episodes defined by diagnosis and/or
medication codes 12 months following cohort entry
were retrieved, together with demographic and clinical
characteristics. Associations between patient
characteristics and odds of having none versus one,
none versus frequent (≥2) and one versus frequent
exacerbations over 12 months follow-up were evaluated
using multivariate logistic regression models.
Results: During follow-up, 23% of patients had
evidence of frequent moderate-to-severe COPD
exacerbations (24% one; 53% none). Independent
predictors of increased odds of having exacerbations
during the follow-up, either frequent episodes or one
episode, included prior exacerbations, increasing
dyspnoea score, increasing grade of airflow limitation,
females and prior or current history of several
comorbidities (eg, asthma, depression, anxiety, heart
failure and cancer).
Conclusions: Primary care-managed patients with
COPD at the highest risk of exacerbations can be
identified by exploring medical history for the presence
of prior exacerbations, greater COPD disease severity
and co-occurrence of other medical conditions.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is characterised by the progressive
deterioration of lung function. In many
patients, the course of the disease is
punctuated by exacerbations, an acute wor-
sening of symptoms which, in severe cases,
can necessitate hospitalisation and even
result in death.1 Exacerbations are the major
cost driver, directly and indirectly, in COPD.2
COPD exacerbations are known to cluster in
time and patients who have experienced one
episode are at increased risk of a recurrent
exacerbation.3 Furthermore, exacerbations
accelerate the deterioration of lung func-
tion,4 which in turn increases the likelihood
and severity of further exacerbations.
Strengths and limitations of this study
▪ We report the results of a retrospective cohort
study of 58 589 patients identified in the UK
Clinical Practice Research Datalink (CPRD) with
spirometry-confirmed chronic obstructive pul-
monary disease (COPD) diagnosis during a
42-month period from 1 April 2009, with the
primary objective of evaluating risk factors for
acute exacerbations of COPD.
▪ Strengths of the study include: the large size of
the cohort; the cohort is representative of the UK
primary care population; the utilisation of the
CPRD, a comprehensive and well-established
electronic medical records database which incor-
porates spirometric scores and dyspnoea grades
recorded as part of the Quality Outcomes
Framework.
▪ The main limitation of this study is that the event
recording of acute exacerbations in the CPRD is
not entirely standardised, necessitating the use
of an algorithm containing prescription records
for oral corticosteroids and antibiotics as well as
primary care visits for exacerbations, and acci-
dent and emergency department and hospital
admissions for COPD to maximise the detection
of exacerbations.
▪ Another possible study limitation is that the true
population of patients with milder airflow
obstruction and those who did not experience
exacerbations may be under-represented in the
data set due to such patients not seeking health-
care or undergoing spirometry.
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Various deﬁnitions are used to mark the start, end,
relapse and recurrence of exacerbations.5 6 Frequent
exacerbations, usually deﬁned as two or more episodes per
year, are the focus of the majority of clinical epidemiology
studies, as they are considered a marker of greater disease
burden and reduced survival.7 However, an increase in fre-
quency of any moderate-to-severe exacerbation events has
been associated with greater disease severity, and the best
predictor of future events is a history of exacerbation(s).7
Previous research into the natural history of COPD
exacerbations has mainly focused on prospective cohorts
of patients who have usually been recruited from sec-
ondary and/or tertiary care. Limited data are available
on the burden of COPD exacerbations in patients who
are managed in primary care. The use of electronic
medical record (EMR) databases allows for the identiﬁ-
cation of very large-scale patient cohorts in a setting
much more representative of clinical practice than pro-
spective studies carried out in selective cohorts.
EMR-based cohorts represent all patients diagnosed and
treated in primary care, with information reﬂecting
real-world healthcare provider decisions and patient
behaviours without any interventions introduced.
Furthermore, the retrospective cohort approach avoids
the potential for behavioural biases associated with selec-
tion and active participation in research, the so-called
‘Hawthorne effect’.8
This retrospective, observational cohort study com-
prises patients who were identiﬁed from primary care
using the UK Clinical Practice Research Datalink
(CPRD-GOLD).
We aimed to evaluate records of episodes of
moderate-to-severe exacerbations of COPD and to deter-
mine the factors associated with COPD exacerbation fre-
quency in patients managed through primary care.
METHODS
Study design
We used a retrospective cohort study design and identi-
ﬁed patients in the CPRD-GOLD who had a record of
COPD diagnosis, deﬁned as ≥1 record of COPD-speciﬁc
Read codes from 1 April 2009 until 30 September 2012.
We then took the ﬁrst record of COPD diagnosis during
this predeﬁned period and assigned it as a cohort entry
date (cohort baseline). We then further limited the
patient cohort to only those with a minimum of 365 days
of available history in the database prior to and subse-
quent to this ﬁrst record (ﬁgure 1).
CPRD-GOLD database
CPRD-GOLD, formerly known as the General Practice
Research Database, is one of the largest computerised
databases of linked anonymised primary care medical
records in the world.9 It reﬂects the complete EMR for
all National Health Service (NHS) primary healthcare
collected from approximately 8% of the population of
England and Wales.10 All medical signs, symptoms,
investigations and diagnoses deemed important for the
continued care of the patients are coded within the
EMR.10 11
The CPRD research group, a part of the UK
Medicines and Healthcare Products Regulatory Agency,
continuously monitors data quality and removes prac-
tices from the database if they fail to maintain the
required standards of data entry.
Patient population
The cohort consisted of patients with a record of COPD
diagnosis between 1 April 2009 and 30 September 2012
who sought care for their condition; see Study design
section. COPD diagnosis was required to be accompan-
ied by spirometry recording consistent with obstructive
disease, deﬁned as a forced expiratory volume in 1s
(FEV1)/forced vital capacity ratio of <0.7 recorded any
time before and up to 3 months from the date of diag-
nosis of COPD record that qualiﬁed the patient to enter
this cohort.
Exacerbations of COPD
An algorithm was assembled to collect data on recorded
events of moderate-to-severe COPD exacerbations from
the 12 months preceding and the 12 months subsequent
to cohort entry date. Moderate exacerbations were
deﬁned as a record of a diagnosis of exacerbation, acute
bronchitis, or the management of COPD with speciﬁc
antibiotics and oral corticosteroids recorded on the
same day or up to 5 days from each other. Admissions to
hospital or visits to the accident and emergency depart-
ment associated with COPD as recorded by general
Figure 1 Patient recruitment flow chart. (COPD, chronic
obstructive pulmonary disease; FEV1, forced expiratory
volume in 1 s; FVC, forced vital capacity).
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practitioners (GPs) were considered as severe exacerba-
tions. An exacerbation episode was deﬁned based on
events recorded over 2 weeks from the initial exacerba-
tion record. The start of an episode was considered to
be the date of the ﬁrst qualifying event. Subsequently, a
14-day rolling window was applied to identify a period of
at least two exacerbation-free weeks in order to ensure
that a relapse was not categorised as a separate exacerba-
tion episode.12 The frequency of individual patients’
exacerbations during the 12 months prior to the start of
observation and also during the 12-month follow-up
period was split into three categories: none, one, or two
or more (frequent) episodes of moderate-to-severe
exacerbation of COPD. The incidence of exacerbation
episodes was also expressed as a rate per person per
year, a sum of the episodes per patient divided by
365 days of follow-up. For a minority of patients, who
would have been ﬁrst diagnosed with COPD during the
year prior to observation period start, we treated their
exacerbation history similarly to those with established
COPD.
Other key study variables
The following variables were also retrieved from the
database using the latest record prior to cohort entry
date: age, gender, smoking status, body mass index
(BMI; or imputed BMI using the latest height and
weight measurements where BMI data were not
recorded), Medical Research Council (MRC) dyspnoea
grade and FEV1 percent predicted.
13
Mean BMI was summarised as both a continuous and
categorical variable using the WHO classiﬁcation of
underweight (<18.5), normal (18.5–24.9), overweight
(25.0–29.9) and obese (≥30).14
The GOLD grade classiﬁcation15 was used to deter-
mine the severity of airﬂow limitation. Owing to the
nature of the data available from CPRD-GOLD, it was
not possible to determine whether the spirometry data
had only been recorded following the administration of
a bronchodilator. However, given that the NHS Quality
Outcomes Framework requires all patients with COPD
to have their COPD diagnosis conﬁrmed with post-
bronchodilator spirometry,16 it is expected that the
majority were recorded following bronchodilator admin-
istration. The categories of airﬂow severity limitation
were deﬁned using the FEV1 cut-off points ≥80% pre-
dicted for mild, ≥50% to <80% predicted for moderate,
≥30% to <50% predicted for severe and <30% predicted
for very severe airﬂow limitation.
MRC dyspnoea grade is a unidimensional measure of
breathlessness related to activity.17 The MRC dyspnoea
scale is equivalent to the modiﬁed MRC (mMRC) scale,
which is an established method in the published litera-
ture. The key difference with the mMRC dyspnoea scale
is a shift in the scoring range: whereas MRC ranged
from 1 to 5, mMRC employs a range from 0 to 4.
Therefore, mMRC Grade 0 is equal to Grade 1 on the
MRC scale.18
Records of diagnoses of selected comorbidities, includ-
ing depression, anxiety and asthma, occurring prior to
the start of the study were retrieved from the database.
Data on the frequency of prescription treatment for
COPD in the 12 months prior to the start of this cohort
study were also collected. Patients who had one or more
records for medication within a therapeutic class, with
the exception of oral corticosteroids, were considered to
use that medication. For oral corticosteroids, four or
more prescriptions within the 12-month period were
considered to indicate regular use rather than acute use
for COPD exacerbation(s). Lastly, the number of
recorded contacts with a GP for any reason in the
12 months before the cohort entry was ascertained and
standardised per 365.25 days.
Statistical analyses
A multilevel multivariable logistic regression was used to
assess risk factors associated with frequency of exacerba-
tions over the 12-month follow-up period: frequent versus
none, frequent versus one, and one versus none. These
analyses were carried out using the PROC LOGISTICS
procedures in SAS V.9.2. All covariates listed in descrip-
tive tables, with the exception of respiratory medications,
were entered into the models. Missing values for BMI
and percent predicted FEV1 values (less than 2% of the
cohort) and MRC dyspnoea score (12% of the cohort)
were not imputed.
The relationships between the number of exacerba-
tion episodes during the 12-month follow-up period and
the percent predicted FEV1 value and MRC dyspnoea
grade were also assessed using Spearman’s correlation
coefﬁcient.
RESULTS
Patients
The cohort consisted of 58 589 patients with COPD
(ﬁgure 1). Overall, 47% of patients were female, mean
age was 69 years and mean FEV1 was 60% predicted.
Incidence of exacerbation
During the 12-month follow-up period, 53% of patients
(n=31 049) had no recorded episodes of moderate-to-severe
exacerbation of COPD, 24% of patients (n=14 189) had
one recorded exacerbation episode and frequent episodes
were recorded in 23% of patients (n=13 351). The rate of
moderate-to-severe exacerbations during the 12-month
follow-up period was 0.89 per person per year. A maximum
of eight episodes per patient was observed.
In comparison to patients with no recorded exacerba-
tion episodes, patients with frequent exacerbations were
more likely to be female (51% vs 44%), had poorer lung
function (mean FEV1 percent predicted: 54% vs 62%)
and more dyspnoea (MRC grade ≥3: 58% vs 39%).
When compared with patients with no recorded exacer-
bation episodes during the 12-month follow-up, patients
with frequent exacerbations were more regularly
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diagnosed with comorbidities including myocardial
infarction, heart failure and depression, and had been
managed with maintenance treatment more often in the
past 12 months (≥1 prescribed inhaled corticosteroid/
long-acting β agonist 68% vs 39%, ≥1 prescribed long-
acting muscarinic antagonist 53% vs 28%; table 1).
Of the patients with no recorded exacerbation epi-
sodes during the 12-month follow-up period, 72% had
no record of a moderate-to-severe exacerbation in the
prior 12 months; 46% of patients who experienced fre-
quent moderate-to-severe exacerbations during the
follow-up period had also experienced two or more
exacerbations in the prior 12 months (ﬁgure 2).
A weak, although statistically signiﬁcant, relationship
was observed between the frequency of COPD exacerba-
tions and the stage of airﬂow limitation (Spearman’s
r=0.16, p<0.001). Thirty-four per cent and 45% of
patients with poor lung function (moderate and severe
airﬂow limitation, respectively) also had no recorded
exacerbations, in contrast to 16% and 19% of patients
who had mild or moderate airﬂow limitation, respect-
ively, with frequent exacerbation episodes (ﬁgure 3A).
Factors associated with exacerbation frequency
Comparison of patients with no exacerbation, one
exacerbation and frequent exacerbations during the
12-month follow-up showed that several factors were
associated with an increased likelihood of prospective
frequent exacerbations; the strongest association was
with prior exacerbations. Experiencing one moderate
exacerbation, compared with none, during the
12 months preceding the start of the study was asso-
ciated with one moderate-to-severe exacerbation occur-
ring (OR=1.9) or frequent (≥2) moderate-to-severe
exacerbations (OR 3.3) occurring during the 12-month
follow-up period (table 2). The OR for frequent (≥2)
moderate-to-severe exacerbations increased to 13.6 if
patients had experienced two or more moderate
episodes, compared with none in the 12 months preced-
ing the start of the study.
The risk of frequent exacerbations compared with
none, during the 12-month observation period,
increased with greater severity of airway limitation;
OR=1.2 for moderate limitation (≥50% FEV1 <80% pre-
dicted) and OR=2.4 for very severe limitation
(FEV1 >30% predicted; table 2). Increasing dyspnoea
grade was also associated with an increased OR for fre-
quent exacerbations compared with no exacerbations,
from 1.4 for MRC2 to 3.0 for MRC5 when compared
with MRC1 (table 2; ﬁgure 3B). The history of speciﬁc
comorbidities was associated with a signiﬁcant increase
in the risk of patients experiencing frequent exacerba-
tions compared with none during the observational
period (table 2). Among the speciﬁc comorbidities
assessed, history of asthma, cancer and depression had
the strongest observed associations with exacerbation fre-
quency, with corresponding ORs for frequent versus no
exacerbations of 1.5, 1.3 and 1.3, respectively (table 2).
Similar risk factors for one versus no exacerbation, albeit
of lower magnitude, were observed as for the risk of fre-
quent versus no exacerbations.
DISCUSSION
We set out to explore COPD exacerbation frequency
and associated factors, using a retrospective cohort
approach, in a large primary care cohort of 58 589
patients in England and Wales. We found marked differ-
ences between patients managed in primary care who
had frequent exacerbations (23% of patients) or one
exacerbation (24%) as compared with patients with no
recorded COPD exacerbations (53%) during the
12-month follow-up period.
The characteristic most strongly associated with
moderate-to-severe exacerbation frequency was a history
of exacerbations. A gradient relationship between
moderate exacerbations in the prior 12 months and pro-
spective moderate-to-severe exacerbations was apparent:
patients who had no exacerbations in the prior
12 months had the lowest risk of future events; patients
who had one exacerbation were at greater risk of future
episodes than those who had none, but were at lower
risk than those who had two or more prior exacerba-
tions; patients with two or more prior exacerbations
were at the highest risk of future exacerbations. Prior
episodes of severe exacerbations also independently
increased the odds of future exacerbations. This result is
in agreement with previously reported ﬁndings.7 When
moderate and severe prior exacerbations are considered
separately, our ﬁndings provide additional supportive
evidence of an independent and ‘dose-like’ relationship
of prior moderate events and future exacerbation risk.
Exacerbation frequency also increased with increasing
grade of airﬂow limitation and similarly with increasing
dyspnoea score. A relationship between exacerbation fre-
quency and symptom severity is well established on the
basis of ﬁndings from prospective studies;19 20 however,
the two factors are semi-independent and patients with
moderate airﬂow limitation can experience recurrent
exacerbations.7 Again, airﬂow limitation and dyspnoea
were associated with a higher risk for any exacerbation
event, not only with frequent events. Likewise, the
slightly increased probability of frequent exacerbations
observed to be associated with females is consistent with
previous reports.19 No relationships between age or
smoking status and exacerbation frequency were
observed.
Finally, we observed a relationship between a prior
diagnosis of selected comorbidities in patient history
and a risk of any future moderate-to-severe exacerba-
tions. Consistent independent associations were
observed between a history of asthma, depression,
anxiety, heart failure and cancer and either one or two
or more exacerbation episodes. It has previously been
reported that COPD exacerbations are associated with
cardiovascular events, including myocardial infarction
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and heart failure,21 and the presence of these comorbid-
ities increases the likelihood of mortality and costs asso-
ciated with exacerbations.2 Likewise, the importance of
comorbid asthma as a risk factor for more frequent
exacerbation and accelerated disease progression has
led to the description of an ‘asthma-COPD overlap syn-
drome’.22 23 It has been estimated that overlap syndrome
may be associated with up to a threefold increase in the
frequency and severity of exacerbations.22 Overlap syn-
drome is typically seen in younger patients with a
smoking burden that is below the average for patients
with COPD, potentially providing a partial explanation
of the absence of observed relationships between age,
smoking status and exacerbation frequency in this study.
Analyses of this large, primary care-based cohort sup-
ported the established hypothesis of the existence of a
‘frequent exacerbator’ phenotype, widely reported in
the COPD literature as an explanation for observations
of a subgroup of patients who experience highly recur-
rent exacerbations.7 24 The pathophysiology underlying
the frequent exacerbator phenotype is not yet fully
understood, and identiﬁcation of the inter-related
factors is potentially of value in aiding the identiﬁcation
of patients who are likely to be at increased risk of
further exacerbations. Early intervention is associated
with faster recovery from exacerbation and improved
health-related quality of life.25
The factors that we have observed to be associated
with any future moderate-to-severe exacerbations are
suggestive of a shared inﬂammatory biological mechan-
ism that gives rise to further exacerbation events and
also leads to a worsening of COPD symptoms. Markers
Table 1 Characteristics of patients with COPD by frequency of recorded exacerbation episodes during 12-month follow-up
Moderate-to-severe exacerbation frequency
None One Two or more
Patient characteristic n=31 049 n=14 189 n=13 351
Age, mean (SD) 69.3 (10.5) 69.8 (10.3) 69.4 (10.2)
Smoking status
Current 10 531 (34) 4667 (33) 4173 (31)
Former 15 988 (51) 7474 (53) 7345 (55)
Never 3312 (11) 1492 (11) 1301 (10)
Other 1218 (4) 556 (4) 532 (4)
Female 13 619 (44) 6831 (48) 6832 (51)
BMI underweight (<18.5 kg/m2) 1327 (4) 641 (5) 751 (6)
BMI normal (18.5–24.9 kg/m2) 10 533 (34) 4810 (34) 4668 (35)
BMI overweight (25.0–29.9 kg/m2) 10 633 (34) 4778 (34) 4274 (32)
BMI obese (≥30.0 kg/m2) 8037 (26) 3760 (26) 3472 (26)
Rate of moderate-to-severe exacerbations in prior
12 months/person/year, mean
0.37 0.74 1.67
Rate of exacerbations with hospital admission
in prior 12 months/person/year, mean
0.07 0.12 0.2
Comorbidities any time in history
Acute myocardial infarction 2530 (8) 1386 (10) 1350 (10)
Congestive heart disease 1857 (6) 1041 (7) 1165 (9)
Depression 3976 (13) 2116 (15) 2393 (18)
≥1 prescription within 12 months before cohort entry
ICS 5789 (19) 2883 (20) 2501 (19)
LABA 2379 (8) 1278 (9) 1295 (10)
ICS/LABA 12 150 (39) 7328 (52) 9133 (68)
LAMA 8618 (28) 5260 (37) 7049 (53)
MRC dyspnoea scale score
MRC 1 6251 (23) 2059 (16) 1165 (10)
MRC 2 11 552 (42) 4765 (38) 3546 (31)
MRC 3 6478 (23) 3487 (28) 3286 (29)
MRC 4 2959 (11) 1876 (15) 2605 (23)
MRC 5 524 (2) 398 (3) 690 (6)
Airflow limitation grade
Mild 5475 (18) 1971 (14) 1398 (10)
Moderate 16 815 (54) 7324 (52) 5693 (43)
Severe 7013 (23) 3855 (27) 4629 (35)
Very severe 1152 (4) 814 (6) 1411 (11)
All data are n (%) unless otherwise stated. Percentages expressed as column %.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA,
long-acting muscarinic antagonist; MRC, Medical Research Council.
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for airway and systemic inﬂammation have been shown
to be associated with exacerbation frequency,1 may pre-
cipitate lung function decline,19 and may also partly
explain the observed relationships between exacerbation
frequency and comorbidities such as cardiovascular
disease21 26 and asthma.27
We found that the characteristics of patients who
experienced at least one exacerbation event during the
follow-up period differed from those who did not have
any exacerbations. This observation replicated earlier
ﬁndings from a clinical cohort of 2138 patients enrolled
in the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study.7
However, it should also be noted that patients who do
not experience exacerbations and have mild airﬂow limi-
tation are less likely to seek healthcare and therefore
less likely to be diagnosed with COPD.28
In this study, an inclusive deﬁnition of exacerbations
was used, encompassing prescription records, as well as
exacerbation event coding and GP records of hospital
admissions and accident and emergency visits. Despite
this, more than half of the cohort experienced no
exacerbations during the 12-month observation period.
It is possible that some exacerbations were unreported
or self-managed at home with rescue packs of antibiotics
and/or oral corticosteroids. Although a spirometry
recording was required for eligibility, patients with
COPD in the present study were identiﬁed based on a
record of their diagnosis from a primary care database
rather than actively recruited when visiting a physician.
Therefore, we cannot ensure that all patients met the
deﬁnition of COPD as per the GOLD guidelines.15
Further, we required all patients to be present in the
database for at least a year postobservation period entry.
A ﬁxed length of follow-up could have introduced a bias
by removing the most severe patients from the analysis.
A strength of this study is the exploration of exacerba-
tion data from a large sample of patients diagnosed with
COPD obtained from a well-established, comprehensive
primary care EMR-based data resource, the CPRD-
GOLD. This resource provides representative coverage
of the patient population in England and Wales, and has
incorporated spirometry and dyspnoea score data as a
part of routine disease management of patients with
COPD since 2004. CPRD-GOLD has previously been
used in COPD research to determine disease prevalence
in the UK29 and to investigate comorbidities in COPD
and asthma.30 31
In conclusion, we demonstrated that, in a primary
population of patients diagnosed with COPD, prior
history of exacerbations (as well as increasing severity of
airﬂow limitation and dyspnoea) and presence of
Figure 2 Frequency of moderate-to-severe chronic
obstructive pulmonary disease (COPD) exacerbations in the
12 months prior to cohort entry in relation to the frequency of
exacerbation episodes during the 12-month follow-up period.
Figure 3 COPD exacerbation frequency during the
12-month follow-up period by (A) airflow limitation stage and
(B) MRC dyspnoea grade (COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 s;
MRC, Medical Research Council).
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comorbidities predict risk of future moderate-to-severe
exacerbation events. We also showed that patients with
prior frequent exacerbations, as well as those with only
one prior moderate exacerbation, are at increased risk
of future exacerbation events. As exacerbations can
accelerate the progression of the disease, our ﬁndings
underline the importance of identifying patients with
COPD who are at risk of exacerbation and intervening
as early as possible. Such identiﬁcation is feasible for a
primary care practitioner based on a review of clinical
history routinely recorded in the UK electronic health
record.
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Table 2 Factors associated with moderate-to-severe exacerbations during the 12-month follow-up period (three-category
multilevel model)
Moderate-to-severe exacerbations during 12-month follow-up
≥2 vs none 1 vs none ≥2 vs 1
Factor OR 95% CI OR 95% CI OR 95% CI
COPD exacerbations, 12 months prior to observation period start
No moderate event Reference
1 moderate episode 3.31 3.12 to 3.51 1.89 1.79 to 1.99 1.76 1.65 to 1.87
≥2 moderate episodes 13.64 12.67 to 14.68 3.11 2.88 to 3.37 4.41 4.11 to 4.74
No hospitalised episode Reference
≥1 hospitalised episode 2.13 1.95 to 2.31 1.49 1.38 to 1.61 1.44 1.32 to 1.57
Airflow limitation level nearest to observation period start
Mild (FEV1 ≥80% predicted) Reference
Moderate (≥50% FEV1 <80% predicted) 1.23 1.13 to 1.33 1.19 1.12 to 1.27 1.04 0.95 to 1.14
Severe (≥30% FEV1 <50% predicted) 1.81 1.66 to 1.98 1.36 1.27 to 1.47 1.37 1.24 to 1.50
Very severe (FEV1 >30% predicted) 2.37 2.08 to 2.70 1.59 1.41 to 1.79 1.56 1.37 to 1.78
MRC dyspnoea scale nearest to observation period start
1 Reference
2 1.39 1.28 to 1.51 1.16 1.09 to 1.23 1.16 1.06 to 1.27
3 1.86 1.70 to 2.03 1.41 1.31 to 1.51 1.32 1.20 to 1.44
4 2.74 2.49 to 3.03 1.55 1.43 to 1.69 1.74 1.57 to 1.93
5 3.02 2.58 to 3.55 1.62 1.39 to 1.88 1.84 1.57 to 2.16
Comorbidities, history of medical diagnosis before observation period start (absence is referent category)
Heart failure 1.2 1.08 to 1.32 1.1 1.00 to 1.20 1.11 1.00 to 1.23
Myocardial infarction 1.13 1.03 to 1.24 1.15 1.06 to 1.24 0.96 0.87 to 1.05
Rheumatological disease 1.12 1.01 to 1.24 1.1 1.01 to 1.21 1.04 0.94 to 1.16
Renal disease 0.9 0.84 to 0.97 0.96 0.91 to 1.02 0.93 0.86 to 1.00
Anxiety 1.16 1.08 to 1.25 1.14 1.08 to 1.22 1.02 0.95 to 1.09
Depression 1.25 1.16 to 1.35 1.1 1.02 to 1.17 1.12 1.04 to 1.21
Asthma 1.51 1.43 to 1.60 1.24 1.19 to 1.30 1.23 1.16 to 1.30
Cancer 1.28 1.19 to 1.38 1.1 1.03 to 1.17 1.14 1.05 to 1.23
Number of contacts with GP, 12 months prior to observation period start
Low: 0–5 Reference
Medium: 6–9 1.02 0.95 to 1.10 1.07 1.00 to 1.13 0.99 0.91 to 1.07
High: ≥10 1.24 1.16 to 1.32 1.18 1.12 to 1.24 1.08 1.01 to 1.16
Sex
Female 1.19 1.13 to 1.26 1.12 1.07 to 1.17 1.07 1.01 to 1.14
Models further adjusted for age, smoking and BMI.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; GP, general practitioner; MRC,
Medical Research Council.
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